Provided by Tiger Trade Technology Pte. Ltd.

Pasithea Therapeutics Corp.

0.8000
+0.00130.16%
Post-market: 0.80000.00000.00%16:00 EST
Volume:231.57K
Turnover:186.91K
Market Cap:18.47M
PE:-0.15
High:0.8700
Open:0.8000
Low:0.7900
Close:0.7987
52wk High:3.79
52wk Low:0.2810
Shares:23.09M
Float Shares:18.52M
Volume Ratio:1.24
T/O Rate:1.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.2115
EPS(LYR):-12.6857
ROE:-89.90%
ROA:-53.70%
PB:1.51
PE(LYR):-0.06

Loading ...

Pasithea Therapeutics Receives Nasdaq Minimum Bid Price Notice

TIPRANKS
·
Yesterday

Nasdaq flags Pasithea Therapeutics for failing $1 minimum bid rule

Reuters
·
Yesterday

Pasithea Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference

Reuters
·
Feb 17

Pasithea Therapeutics Corporation Held Special Shareholder Meeting

Reuters
·
Jan 29

Pasithea Therapeutics: Buy Rating on Differentiated PAS-004, 2026 Clinical Catalysts, and Strengthened Cash Runway

TIPRANKS
·
Jan 14

Pasithea Therapeutics Announces Data Release Timeline for PAS-004 Clinical Trials in NF1 and Advanced Cancer

Reuters
·
Jan 13

Pasithea Therapeutics Corp - to Present Nf1-Pn Study Data in H2 2026

THOMSON REUTERS
·
Jan 13

Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines

GlobeNewswire
·
Jan 13

Pasithea Therapeutics Unveils Investor Presentation Highlighting Next-Generation MEK Inhibitor PAS-004 for Cancer and NF1

Reuters
·
Jan 12

Pasithea Therapeutics Corporation Announces Date for Upcoming Special Meeting of Stockholders

Reuters
·
Dec 20, 2025

Pasithea Therapeutics Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
Dec 08, 2025

HC Wainwright Initiates Coverage on Pasithea Therapeutics With Buy Rating, $3 Price Target

MT Newswires Live
·
Dec 08, 2025

Pasithea Therapeutics Corp. : H.c. Wainwright Initiates Coverage With Buy Rating

THOMSON REUTERS
·
Dec 08, 2025

Press Release: Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock

Dow Jones
·
Dec 02, 2025

Form 4 | Pasithea Therapeutics Corp. Director Lawrence Steinman purchased 133,333 Shares.

Filings Track
·
Dec 01, 2025

Pasithea Therapeutics Director Lawrence Steinman Reports Acquisition of Common Shares

Reuters
·
Dec 01, 2025

Pasithea Therapeutics Director Simon Dumesnil Acquires Common Shares

Reuters
·
Dec 01, 2025

US Equity Markets Close Higher During Thanksgiving Week as Interest Rate Cut Expectations Remain Strong

MT Newswires Live
·
Nov 29, 2025

Top Midday Gainers

MT Newswires Live
·
Nov 29, 2025

Crude Oil Gains 1%; Tilray Brands Shares Plunge

Benzinga
·
Nov 29, 2025